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TherapeuticapplicationofsiRNArequiresdeliverytothecorrectintracellularlocation,tointeractwiththeRNAimachinerywithin
the target cell, within the target tissue responsible for the pathology. Each of these levels of targeting poses a signiﬁcant barrier. To
overcomethesebarriersseveralstrategieshavebeendeveloped,suchaschemicalmodiﬁcationsofsiRNA,viralnucleicaciddelivery
systems, and nonviral nucleic acid delivery systems. Here, we discuss progress that has been made to improve targeted delivery of
siRNA in vivo for each of these strategies.
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INTRODUCTION
The functional mediators of RNA interference (RNAi) are
small interfering RNAs (siRNA) [1, 2]. These double-
stranded RNA molecules are typically 19 to 23 nucleotides
in length, and consequently have a molecular weight of ap-
proximately 13 to 15kd and 38 to 46 negative charges. As a
consequence, passive transport over the lipophilic cell mem-
b ra n ei sp o o r[ 3–5]. At the same time, intracellular entry and
translocation into the cytoplasm (and/or nucleus), where the
RNAi machinery is located, is a prerequisite, for gene silenc-
ingactivity[6–9].Moreimportantly,forinvivoapplications,
intracellular entry into the target cell within the diseased tis-
s u ei sr e q u i r e da n ds h o u l dl e a dt oa p p e a r a n c ei nt h ec y t o -
plasm to silence the mRNA of interest (Figure 1). Ideally,
siRNA should therefore be targeted to three levels: to the tar-
get tissue, the target cell type, and the subcellular compart-
ment.
Primary obstacles for achieving this in vivo include com-
petitive uptake by nontarget cells, excretion in urine, degra-
dation by nucleases, and endosomal trapping.
Some literature reports claim entry of siRNA in the tar-
get cells of the target tissue after intravenous injection [10].
The observations have been attributed to translocation of
siRNAoverthecellmembranebyadsRNA-receptor,referred
to in Caenorhabditis elegans as SID-1,which is responsible
in this organism for systemic spreading of the silencing ef-
fects [11]. Indeed, overexpression of the mammalian homo-
logue increases the intracellular uptake of siRNA [12]. In
contrast, “naked” siRNA is used by many researchers as a
negative control which fails to produce silencing eﬀects af-
ter injection in vivo and even after prolonged incubation of
cells with high siRNA concentrations in vitro. This lack of
activity of “naked” siRNA indicates that not all cell types ex-
press (enoughof)theSID-1homologue,to observesilencing
eﬀects.Inaddition,therapidremovalof“naked”siRNAafter
intravenous administration from the circulation, with more
than 99% of the injected dose renally excreted and taken up
by liver Kupﬀer cells within minutes, makes a very small per-
centage of the administered dose available for the target tis-
sue. This small percentage is additionally subject to nucle-
ase degradation. Therefore, intravenous injection of naked
siRNA relying on passive targeting of the diseased tissue, and
SID-1 homologue-mediated target cell uptake seem to be in-
eﬃcient and as yet unpredictable.
Local injection at the site of pathology avoids many
of the diﬃculties encountered after intravenous adminis-
tration, most notably the rapid elimination, and is there-
fore a popular approach to increase target tissue concen-
trations of siRNA. With this approach chances of obtain-
ing suﬃcient intracellular levels of siRNA for therapeutic ef-
fects are increased [13, 14]. Furthermore, helper molecules
(like cationic lipids or polymers) or physical methods (like
electroporation, sonoporation, or hydrodynamic pressure)
can be employed to facilitate intracellular entrance of siRNA
[13, 15–19]. In addition, local production of siRNA by genes
encoding for short hairpin RNA (shRNA) can ensure pro-
longed levels of the dsRNA intracellularly [20, 21]. The en-
coding genes can be delivered by viral vectors or one of the
aforementioned nonviral methods.2 Journal of Biomedicine and Biotechnology
Unfortunately, local administration is not always feasi-
ble because the target tissue cannot be reached, or covers an
area that is too large to be feasible for a local injection proto-
col.Inaddition,usinglocalinjection(possiblysupplemented
with helper molecules or physical stimuli) selectivity in de-
livery to nontarget and target cell types has usually not been
takenintoaccount.Thisisanimportantaspectwhenconsid-
ering the nonspeciﬁc eﬀects that can be induced by dsRNA.
Over the past few years, it has become clear that cells can
respond strongly to siRNA by diﬀerent proinﬂammatory re-
actions depending on cell type, siRNA sequence, and intra-
cellular location [22–24]. These eﬀects can be intensiﬁed by
employing cationic helper molecules [25], an eﬀect probably
mediated by a change in the intracellular traﬃcking of the
dsRNA [23]. As a consequence, nontarget cells may also take
up siRNA and respond with induction of proinﬂammatory
pathways in addition to the therapeutic RNAi eﬀects within
the target cells at the diseased site.
In this review we will focus on strategies for targeted
siRNAdeliverythataredesignedtoimproveaccumulationof
siRNA at three in vivo levels of delivery: at the target tissue,
thetargetcell,andattheintracellulartargetsiteofaction.We
will concentrate on delivery approaches for systemic admin-
istration as such systems have broadest applicability. Three
approaches will be discussed:
(1) chemical modiﬁcations of siRNA,
(2) viral nucleic acid delivery systems,
(3) nonviral nucleic acid delivery systems.
Most attention will be given to in vivo delivery strategies, as
in vitro targeting studies often do not represent a fair evalu-
ation of the many barriers that exist in vivo, possibly imped-
ing eﬃcient and site-speciﬁc delivery (eg, phagocyte uptake,
uptake by competing cell types, excretion, intracellular pro-
cessing, and siRNA (delivery system) stability).
CHEMICAL MODIFICATIONS
The nuclease sensitivity and poor tissue distribution/mem-
brane permeation qualities of siRNA provide a reason to
investigate possible chemical modiﬁcations that would im-
prove these characteristics which would not interfere with
the silencing eﬃciency of the molecules. Several strategies
havebeenproposedtoimprovenucleaseresistanceandtarget
cell uptake.
Increasingnucleaseresistance
Chemical modiﬁcations in the nucleobases, sugars, and the
phosphate ester backbone of siRNA can reduce siRNA sen-
sitivity to nucleases [26–28]. Initial studies centered on
the tolerance of the RNAi system for modiﬁcations in the
two RNA strands [29]. A number of chemical modiﬁca-
tions have been proposed to increase nuclease resistance,
like boranophosphates [30], 4 -thioribonucleosides, phos-
phorothioates, 2 deoxy-2  ﬂuorouridine, 2 -O-methyl, 2 -O-
(2-methoxyethyl), and locked nucleotides [31–36]. All of
these chemically modiﬁed siRNAs were still able to induce
Figure 1: Three levels of targeting: preferably, siRNA should be tar-
geted to the diseased tissue (I). Within this tissue it should be deliv-
ered to the correct cell type for silencing the mRNA of interest (II).
Following entry of the target cell, siRNA should be delivered to the
cytoplasm (and/or nucleus) to interact with the components of the
RNAi machinery (III).
siRNA-mediating gene silencing provided that the modiﬁ-
cations were absent in speciﬁc regions of the siRNA and
included to a limited extent. These speciﬁc restrictions re-
garding position and degree of modiﬁcations were depen-
dent on the characteristics of the incorporated modiﬁcation.
Although increased nuclease resistance of siRNA would be
expected to increase in vivo silencing eﬀects, Layzer et al
showed that this is not necessarily the case. They studied si-
lencing eﬀects in the liver after hydrodynamic injection, and
showed that unmodiﬁed siRNA had a similar potency as the
stabilized version [36].
In contrast, chemical modiﬁcations were shown to en-
hance therapeutic eﬀects in a mouse model of hepatitis B
virusinfection.Chemicallymodiﬁed siRNAdesigned against
a conserved region of the hepatitis B virus was shown to de-
crease viral DNA, hepatitis B surface antigen levels in serum,
aswellasviralRNAlevelsinliverover1000-foldascompared
to chemically modiﬁed control siRNA and buﬀer-treated an-
imals in a hydrodynamic injection protocol. The beneﬁt of
chemically modiﬁed siRNA was supported by the fact that
indicators of viral infection were 30-fold higher in animals
treated with unmodiﬁed siRNA [37].
Increasingintracellularuptake
Several approaches have been developed where chemical
modiﬁcations have been introduced to enhance intracellular
uptake of siRNA. Liao and Wang developed poly-2 -O-(2,4-
dinitrophenyl) modiﬁed siRNA. The enhanced lipophilicity
of this siRNA allows passive diﬀusion over the cell mem-
brane, while at the same time enhancing nuclease resistance.
This approach has only been investigated in vitro and shows
that chemical modiﬁcation can enhance siRNA potency at
both fronts. As a result the silencing eﬀects of the chemi-
cally modiﬁed siRNA speciﬁc for insulin-like growth factor
receptor were strongly enhanced as compared to unmodiﬁed
siRNA [38].Sabrina Oliveira et al 3
In a similar setup, membrane permeant peptides (pen-
etratin and transportin) were coupled to siRNA to facilitate
their intracellular uptake. By coupling the peptide via a re-
ducible disulﬁde linker, the bulky peptides are expected to be
cleaved-oﬀ liberating the siRNA in the cytoplasm. The ap-
proach was validated in vitro, thus supporting wide applica-
tion of the basic technology. Nevertheless, cell speciﬁcity is
lacking [39].
Probably the furthest developed work on chemically
modiﬁed siRNAs has been reported by Soutcheck et al [40].
They have developed siRNAs with partial phosphorothioate
backbone modiﬁcations and 2 -O-methyl sugar variations
on the sense and antisense strands to promote nuclease re-
sistance, while at the same time cholesterol was conjugated
to the 3  end of the sense strand using a pyrrolidine linker to
change tissue distribution. The cholesterol-modiﬁed siRNA
silenced reporter gene expression in vitro in the absence
of transfection agents, something not observed for unmod-
iﬁed siRNAs. Probably the interaction of the cholesterol
with serum components in the culture medium improved
siRNAtranslocationoverthecellularmembrane.Thecholes-
terol modiﬁcation particularly enhanced binding of siRNA
to serum albumin, probably explaining the prolonged circu-
lation half-life measured after intravenous injection as com-
pared to unmodiﬁed siRNA. In addition to a prolonged pres-
ence in the circulation, cholesterol-modiﬁed siRNAs were
detected in liver and jejunum at concentrations of 100–
200ng per gram tissue 24 hours after the last injection of
50mg/kgdoses.Theselevelsweresuﬃcienttoreducethelev-
els of the apolipoprotein apoB-100 in plasma by 31–68%.
This reduction was paralleled by a 37% reduction in over-
all cholesterol levels, and reduction in high-density lipopro-
tein, low- density lipoprotein, and chylomicron levels. De-
spite these impressive results using relatively simple modi-
ﬁcations, the doses of chemically modiﬁed siRNAs needed
are relatively high and seem to underline that changing tis-
sue distribution of siRNA in favor of target cell uptake by
conjugationwithcomparativelysmallchemicalgroupsisdif-
ﬁcult to achieve. At the same time, small molecular weight
modiﬁcations seem to be needed to preserve correct inter-
action with the RNAi enzymes. Cleavable linkers for cou-
pling of bulkier modiﬁcations may be an approach to avoid
these problems. In conclusion, chemical modiﬁcations do
promise important advances regarding nuclease resistance
and reduced induction of the stress response. Invitrogen
has developed a second-generation siRNA, known as Stealth
RNAi, in which chemical modiﬁcations are designed to in-
crease the speciﬁcity of RNAi eﬀects by allowing only the
antisense strand to eﬃciently enter the RNAi pathway and
eliminating induction of interferon-related pathways. Oth-
ers have also demonstrated that sequence and modiﬁcations
can strongly inﬂuence intensity of silencing eﬃciency and
inﬂammatory reactions, providing tools to optimize these
[41, 42].
Taken together, chemical modiﬁcations can markedly in-
creasenucleaseresistanceofsiRNAimprovingcellularpersis-
tence and conjugation with translocating/hydrophobic func-
tional groups can increase membrane permeation. Strategies
to aﬀect tissue distribution proﬁles of siRNA with chemical
modiﬁcations seem more diﬃcult.
VIRAL NUCLEIC ACID DELIVERY
Virusesareatpresentthemosteﬃcientgenedeliveryvectors.
After cell binding they are capable of delivering their nucleic
acidpayloadintracellularlyinaproﬁcientwayalongwithnu-
clear localization. Although virus-mediated delivery meth-
ods are usually based on delivery of genes encoding shRNA,
fewapproachesusedvirusestodeliverchemicallysynthesized
siRNA in vivo [43, 44].
DeliveryofchemicallysynthesizedsiRNA
In this approach, reconstituted viral envelopes derived from
inﬂuenza virus are used to encapsulate and deliver siRNAs.
The reconstituted membrane vesicles contain the inﬂuenza
virus spike protein hemagglutinin and additionally added
cationic lipids. This protein is responsible for binding to and
fusion with cellular membranes. The siRNA-loaded vesicles
are taken up by receptor-mediated endocytosis, and are able
to escape endosomal degradation by fusion with the endo-
somal membrane. Functional siRNA delivery was demon-
strated in vitro, while in vivo uptake by macrophages in
the peritoneal cavity was demonstrated after intraperitoneal
injection. A similar approach, described siRNA delivery by
simian virus SV40-based particles in vitro in lymphoblastoid
cells [44]. As with many viral approaches, drawbacks of the
systems are the diﬃculties of repeated administration and
limited control over transduced cell type.
DeliveryofDNAencodingsiRNA/shRNA
A number of studies investigated the use of DNA encoding
for shRNA delivered by viruses for gene silencing in vivo. In-
travenous injection of 5 × 109 plaque forming units (pfus)
recombinant adenovirus expressing shRNA targeting hepati-
tis B virus transcripts in mice with active replication of the
hepatitis B virus, showed almost complete inhibition of vi-
ral protein production [45]. This in turn led to arrest of vi-
ral replication at day 17 after viral infection. The inhibitory
eﬀect persisted for at least 10 days. Interestingly, there ap-
peared to be a fraction of viral protein that was not suscep-
tible to RNAi-mediated silencing, which is suggested to be
attributable to protection through binding of their mRNA to
speciﬁc proteins. The exact nature of this protection and its
possible involvement in RNAi resistance remains to be deter-
mined.
Uchida et al used expression of two separate siRNA
strandsagainstsurvivinbyadenoviraltransductiontoinhibit
tumor growth. Survivin is a protein that inhibits cancer cell
apoptosis. Mice bearing subcutaneous U251 glioma tumors
were treated with intratumoral injections of 1010 viral parti-
cles on three consecutive days every twenty days, ultimately
leading to four-fold smaller tumors at day 48 after start of
treatment as compared to empty adenoviral vector and ade-
noviral vector expressing irrelevant siRNA [20].4 Journal of Biomedicine and Biotechnology
These studies demonstrate the possibilities for single in-
travenous or multiple local injections of virally delivered
DNA encoding si/shRNA for gene silencing. This strategy
has been further conﬁrmed in a number of diﬀerent in vivo
models and with a number of diﬀerent vectors, like intracra-
nial delivery of lentivirus-produced shRNA for inhibition of
reporter gene expression in cortical neurons [46], intraperi-
toneal delivery of lentivirus-produced shRNA for inhibition
o fv i r a lc y c l i nt op r e v e n tp r i m a r ye ﬀusion lymphoma in
mice[47],intramuscularorintraspinaldeliveryoflentivirus-
produced shRNA for inhibition of mutant SOD1 in amy-
otrophic lateral sclerosis [48, 49], and ex vivo delivery of
lentivirus-produced shRNA for inhibition of CC-chemokine
receptor 2 in hematopoietic cells in mice [50].
Taken together, the viral DNA-based sh/siRNA delivery
process is very eﬃcient: binding to the target cell surface
and subsequent transduction, carrier stability, and protec-
tion against nucleases appear satisfactory [51–54]. However,
as the discussed approaches illustrate, viruses usually lack se-
lectivity for the target cell type. To improve speciﬁcity, the
natural tropism of viruses for certain cell types may be used.
Currently, much attention is focused on redirecting the nat-
ural preferred cell type of viruses towards therapeutically in-
teresting receptors on the surfaceof target cells. Examples in-
clude the retargeting of murine coronavirus to the human
e p i d e r m a lg r o w t hf a c t o rr e c e p t o r[ 55], directing adenovirus
via ﬁbroblast growth factor ligand towards its associated re-
ceptor(FGFR1)fordeliverytoglioma,oradenoviraldelivery
to angiogenic endothelium via RGD-peptides binding alpha
v-integrins [56]. However, such approaches have not been
tried as yet in combination with RNAi-mediated gene silenc-
ing in vivo.
The strength of the viral delivery approach is the eﬃcient
transduction of cells. Challenges that remain are the control
over transduced cell type, especially after systemic adminis-
tration. In addition, inﬂammatory reactions, immunogenic-
ity, and oncogenic transformations continue to be important
safety considerations for viral vectors that need to be ad-
dressed [57, 58].
Nonviralnucleicaciddelivery
Whereas viral vectors possess many of the desired character-
istics for eﬃcient nucleic acid delivery, nonviral vectors pos-
sess several advantages. Important beneﬁts of synthetic vec-
tor systems are the safety (related to their lack of immuno-
genicity and low frequency of integration) and ease of large-
scale production. In addition, they can accommodate a wide
variety of nucleic acid sizes and they allow easy modiﬁcation.
On the downside, transfection eﬃciency can be a limiting
factor.
To face this weakness, many functional groups need to
be incorporated into nonviral nucleic acid delivery systems.
A cationic functional group is usually required to bind and
condense the nucleic acid, thereby protecting it against nu-
cleases and (important for siRNA) increasing the apparent
molecular weight above the renal clearance cut-oﬀ. In addi-
tion, some cationic compounds are being used as endosomal
escape enhancers. Due to the resulting positive charge, com-
plexestendtoformaggregatesbybindinginthebloodstream
to negatively charged biomolecules. As a result, their clear-
anceisusuallyrapid.Moreover,suchcationiccomplexespos-
sess a propensity to interact with virtually any cell type they
encounter, creating a need to insulate the interactive sur-
face of the particle to promote speciﬁcity. For that purpose,
shielding groups can be added to enhance colloidal stability
and reduce surface charge thereby avoiding nonspeciﬁc cell
uptake. To restore cell interaction in a target-speciﬁc manner
targeting ligands can be coupled to induce site-speciﬁc bind-
ing and uptake. In the case of delivery of DNA encoding for
shRNA by non-viral delivery systems, nuclear translocation
of the DNA is often inadequate. As such, the cytoplasmic site
of activity of chemically synthesized siRNA provides an im-
portant advantage.
DeliverysystembasedonRNA
AsystemconsistingcompletelyofRNAwasproposedbyGuo
et al [59]. Their system is based on the packaging RNA of the
DNA-packaging motor of bacteriophage phi29, which can
spontaneously form dimers via interlocking right- and left-
hand loops. By attaching the siRNA to one loop and an RNA
aptamertoCD4totheother,acancercelltargetedsystemwas
created that could silence survivin gene expression in vitro.
Alternatively, the system could also be targeted by folate.
Cationicdeliverysystems
Unshielded, untargeted complexes of siRNA with cationic
polymers or lipids, can provide local or systemic transfec-
tion of a suﬃcient number of target cells for therapeu-
tic eﬀects. Several studies employed cationic lipids to com-
plex siRNA to silence, amongst others,TNF-alpha in in-
traperitoneal macrophages after intraperitoneal administra-
tion [60], delta opioid receptor in spinal cord and dorsal
root ganglia after intrathecal administration [61], polo-like
kinase-1 in bladder cancer after intravesical administration,
and c-raf-1 in prostate cancer cells after intravenous admin-
istration [62]. Although, a suﬃcient number of cells must
have been reached as silencing is observed, it is fair to as-
sume that a large part of the dose will arrive in nontarget
cells. In view of the nonspeciﬁc eﬀects that can be induced
by cationic lipids themselves and in particular in combina-
tion with dsRNA, this may severely hamper therapeutic ap-
plication [25, 63].
A variety of other cationic compounds have also been in-
vestigatedforsiRNA-deliverypurposes.Alinearlowmolecu-
lar weight form of the cationic polymer poly(ethylene imine)
(PEI) has been used for treatment of (subcutaneously im-
planted) ovarian carcinoma in mice [64]. After intraperi-
toneal administration complexed siRNA was primarily re-
covered from muscle, liver, kidney, and tumor. Interestingly,
the major organ where PEI nucleic acid-complexes are usu-
ally recovered, the lung, was largely avoided. Importantly, si-
lencing of Her-2 with these polyplexes inhibited ovarian car-
cinoma growth in vivo.Sabrina Oliveira et al 5
Atelocollagen (a highly puriﬁed type-I collagen of calf
dermis digested by pepsin), was shown to be a suitable ve-
hicle for local delivery of siRNA [17, 65]. In addition, when
administered intravenously, atelocollagen-siRNA was able to
localize at sites of tumor mestastases and inhibit metastasis
outgrowth [66]. More speciﬁcally, tumor levels increased ∼
6-foldascomparedtolevelsafter“naked”siRNAadministra-
tion (from 0.7 to 4.3ng/mg after injection of 25μgs i R N A ) .
This eﬀect was, albeit less pronounced, also seen in the other
organs investigated (ie, liver, lungs, kidneys, and spleen)
demonstrating that the enhanced tissue uptake is not ex-
clusively tumor-speciﬁc. Nevertheless, delivery of these lev-
els of siRNA silencing EZH2 (enhancer of zest homologue-
2, a gene overexpressed in hormone-refractory metastatic
prostate cancer) or p110-α (a phosphatidylinositol 3-kinase
regulating cell survival, proliferation, and migration) re-
sulted in strong inhibition of growth of bone metastases
of prostate cancer cells. Importantly, siRNA-atelocollagen
complexes failed to induce nonspeciﬁc proinﬂammatory re-
sponses like secretion of IFN-α and IL-12.
Targetedcationicdeliverysystems
A targeted amino-acid-based system was based on the
cationic peptide protamine [67]. To the system’s protamine-
block the C-terminus of the heavy chain Fab fragment of an
HIV-1envelopeantibody wascoupledtoformaproteincon-
struct known as F105-P. This system was highly eﬃcient in
binding to and transfection of cells expressing HIV-envelope
protein, although it is unclear why the HIV-envelope protein
wouldbeinternalized. Importantly, expression ofinterferon-
β,2  ,5  -oligoadenylate synthetase, and Stat-1, as indicators
of nonspeciﬁc eﬀects, were not increased upon siRNA trans-
fection of HIV-envelope-expressing melanoma cells. In addi-
tion, when these cells formed subcutaneous tumors in vivo,
30% of cells took up ﬂuorescent siRNA when delivered by
F105-P after intravenous administration. Naked siRNA was
not taken up, nor was F105-P-siRNA delivered to cells that
wereenvelope-proteinnegative.Deliveryofacombinationof
siRNAs against c-myc, MDM2, VEGF strongly inhibited tu-
mor growth in vivo when delivered using the F105-P system.
This combination of siRNAs attacking the tumor at multiple
fronts is an important advantage of the siRNA technology as
it allows simultaneous interference with a number of diﬀer-
ent pathways, while the delivery problem for each individ-
ual drug molecule (siRNA) remains the same. The versatility
of this targeted system was demonstrated by exchanging the
HIV-envelope antibody for an ErbB2-antibody changing the
speciﬁcity of the system to ErbB2-positive breast carcinoma
cells.
In a cationic lipid-based approach, Pirollo et al coupled
a transferrin receptor single chain Fv region antibody frag-
ment to the surface of cationic DOTAP: DOPE complexes
containing siRNA [68]. They evaluated the targeting poten-
tial of these systems in diﬀerent murine tumor models: an
orthothopically implanted pancreatic carcinoma (that pro-
duced spontaneous metastases), an orthotopically implanted
prostate carcinoma, and intravenously administered breast
carcinoma cells giving rise to metastases in the lung. In all
these models, speciﬁc accumulation of ﬂuorescently labeled
siRNA complexed to the targeted cationic lipid particles at
the site of the malignancy could be demonstrated as com-
pared to surrounding normal tissue and liver. The question
whether targeted delivery resulted in gene silencing was not
addressed.
Shieldedtargetedcationicdeliverysystems
Targeted cationic systems have the important advantage that
they possess a recognition signal for speciﬁc interaction with
the target cell type. However, the cationic surface may also be
abletointeractwithbiomoleculesornontargetcells.Assuch,
shielding of the cationic surface may further enhance target
cell speciﬁcity by reducing nontarget tissue uptake and may
additionally increase colloidal stability of the siRNA com-
plexes.
In our studies we focused on the cationic polymer PEI
coupled to PEG as shielding polymer. To the distal end of the
PEG-chain a cyclic RGD-peptide was coupled. This peptide
is a high-aﬃnity ligand for alpha v-integrins that are overex-
pressed on angiogenic endothelial surfaces [69]. Tissue dis-
tribution studies in vivo of ﬂuorescently labeled siRNA in
subcutaneous neuroblastoma-bearing mice showed that in-
jection of “naked” siRNA did not produce appreciable tumor
levels, but rather rapid clearance into the urine. PEI-siRNA
complexes also lacked the production of high ﬂuorescence in
the tumor, but did increase liver and especially lung levels.
The ﬂuorescence appeared punctuate in both latter tissues,
probably reﬂecting formation of aggregates in the circula-
tion.
When the PEG-shielded, targeted nanoparticles were
used, ahigherlevelofspeciﬁcityforthetumorandlowerlev-
els of ﬂuorescence in the lung and liver were observed. In a
therapeutic setting, siRNA against murine VEGF receptor-
2 was used, since the receptor is one of the driving factors
of tumor angiogenesis. Delivery to host tumor endothelium
is required to inhibit tumor proliferation. Eﬃcacy studies
with VEGFR2-speciﬁc siRNA complexed in RGD-PEG-PEI
nanoparticles resulted in strong inhibition of sc neuroblas-
toma growth rate, which was sequence-speciﬁc. These exper-
iments suggest that the targeted shielded nanoparticles in-
deed deliver the siRNA to the angiogenic endothelial cells. In
line with these ﬁndings, the reduced tumor growth rate was
paralleled by a reduction in blood vessels in the periphery of
the tumor and changes in vascular morphology of remain-
ing vessels, supporting an antiangiogenic mechanism of ac-
tion. These results were supported by studies in a model of
pathological angiogenesis in the eye [70], again demonstrat-
ing vasculature-speciﬁc delivery and inhibition of angiogen-
esis leading to therapeutic eﬀects. Importantly, the studies in
the eye also showed that combining siRNAs against diﬀer-
ent driving factors in the VEGF-pathway in the same deliv-
ery system improved therapeutic eﬀects. Attacking the var-
ious receptors and growth factors simultaneously seems to
oﬀer advantages. Especially in multifactorial diseases, where
functional redundancy is likely, this cocktail approach seems
to oﬀer important beneﬁts.6 Journal of Biomedicine and Biotechnology
Chemical modiﬁcations
(a)
Viral nucleic acid delivery
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Nucleic acid
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Lipophilic modiﬁcation
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Nonviral nucleic acid delivery
Figure 2: Strategies for siRNA delivery. Strategies are based on (a) chemical modiﬁcations of siRNA, (b) targeting of siRNA using viral
vectors, or (c) nonviral delivery systems.
Synthetic nonviral delivery systems are a diverse class of
molecules used in diﬀerent nucleic acid delivery strategies
that range from relatively simple cationic complexation for
local administration to targeted shielded systems for intra-
venous injection. Their adaptability to speciﬁc targeting re-
quirements is an important advantage, although optimiza-
tion of delivery eﬃciency continues to remain important.
FINAL REMARKS
Over the last decades, research on the promises of nu-
cleic acids for therapeutic intervention and the diﬃculties
encountered in turning these promises into clinical real-
ity has provided a clearer picture of the development steps
that are needed to transform nucleic acids into actual drug
molecules.AsaresultsiRNAhasbeenabletomakearemark-
ablerapidprogressfrominitialdiscoveryasfunctionalmedi-
ator of RNA interferencein mammalian cells in 2001 to three
clinical trials at the end of 2005: two in age-related macular
degeneration, the other in respiratory syncytial virus infec-
tion [71]. Nevertheless, the choice of the diseases also reﬂects
the delivery diﬃculties encountered for this class of nucleic
acids. These diseases were selected partly because the target
cell delivery problems are relatively low as these pathologies
are conﬁned to speciﬁc and accessible sites. To further im-
prove target speciﬁcity, also in view of possible adverse ef-
fects occurring when siRNA is processed by nontarget cells,
andtoallowapplicationofsiRNAforsystemictreatmentsev-
eral strategies can be proposed (Figure 2). Taken together
they serve to increase nuclease resistance, to reduce renalSabrina Oliveira et al 7
excretion/speciﬁc cell uptake, to promote uptake by the tar-
get cells, and to ensure correct intracellular traﬃcking to the
site of action. As the ﬁrst preclinical proofs of principle have
been delivered showing therapeutic eﬀects of locally and sys-
temically delivered siRNAs, it is expected that these strate-
gies will soon translate into viable clinical development pro-
grams.
REFERENCES
[1] SontheimerEJ,CarthewRW.Silencefromwithin:endogenous
siRNAs and miRNAs. Cell. 2005;122(1):9–12.
[2] Zamore PD, Haley B. Ribo-gnome: the big world of small
RNAs. Science. 2005;309(5740):1519–1524.
[3] SioudM.OnthedeliveryofsmallinterferingRNAsintomam-
malian cells. Expert Opinion on Drug Delivery. 2005;2(4):639–
651.
[ 4 ] L uP Y ,X i eF ,W o o d l eM C .I nvi v oa p p l i c a t i o no fR N Ai n t e r f e r -
ence: from functional genomics to therapeutics. Advances in
Genetics. 2005;54:117–142.
[5] Schiﬀelers RM, Woodle MC, Scaria PV. Pharmaceutical
prospects for RNA interference. Pharmaceutical Research.
2004;21(1):1–7.
[6] Chiu YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a corre-
lation between siRNA localization, cellular uptake, and RNAi
in living cells. Chemistry & Biology. 2004;11(8):1165–1175.
[7] Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R.
MicroRNA-dependent localization of targeted mRNAs to
mammalian P-bodies. Nature Cell Biology. 2005;7(7):719–723.
[8] Sen GL, Blau HM. Argonaute 2/RISC resides in sites of mam-
malianmRNAdecayknownascytoplasmicbodies.Nature Cell
Biology. 2005;7(6):633–636.
[9] Robb GB, Brown KM, Khurana J, Rana TM. Speciﬁc and po-
tent RNAi in the nucleus of human cells. Nature Structural &
Molecular Biology. 2005;12(2):133–137.
[10] Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW,
Whang EE. Systemic siRNA-mediated gene silencing: a new
approach to targeted therapy of cancer. Annals of Surgery.
2004;240(4):667–674. discussion 675–676.
[11] Feinberg EH, Hunter CP. Transport of dsRNA into cells by the
transmembraneproteinSID-1.Science.2003;301(5639):1545–
1547.
[12] Duxbury MS, Ashley SW, Whang EE. RNA interference: a
mammalian SID-1 homologue enhances siRNA uptake and
gene silencing eﬃcacy in human cells. Biochemical and Bio-
physical Research Communications. 2005;331(2):459–463.
[13] Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieber-
man J. Small interfering RNA targeting Fas protects mice
against renal ischemia-reperfusion injury. Proceedings of the
National Academy of Sciences of the United States of America.
2004;101(41):14883–14888.
[14] Chae SS, Paik JH, Furneaux H, Hla T. Requirement for sphin-
gosine 1-phosphate receptor-1 in tumor angiogenesis demon-
strated by in vivo RNA interference. The Journal of Clinical In-
vestigation. 2004;114(8):1082–1089.
[15] Akaneya Y, Jiang B, Tsumoto T. RNAi-induced gene silencing
by local electroporation in targeting brain region. Journal of
Neurophysiology. 2005;93(1):594–602.
[16] Schiﬀelers RM, Xu J, Storm G, Woodle MC, Scaria PV. Ef-
fects of treatment with small interfering RNA on joint inﬂam-
mation in mice with collagen-induced arthritis. Arthritis and
Rheumatism. 2005;52(4):1314–1318.
[17] Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-
mediated synthetic small interfering RNA delivery for eﬀec-
tive gene silencing in vitro and in vivo. Nucleic Acids Research.
2004;32(13):e109.
[18] Leng Q, Mixson AJ. Small interfering RNA targeting Raf-1 in-
hibitstumorgrowthinvitroandinvivo.CancerGeneTherapy.
2005;12(8):682–690.
[19] Tsunoda S, Mazda O, Oda Y, et al. Sonoporation using
microbubble BR14 promotes pDNA/siRNA transduction to
murine heart. Biochemical and Biophysical Research Commu-
nications. 2005;336(1):118–127.
[20] Uchida H, Tanaka T, Sasaki K, et al. Adenovirus-mediated
transfer of siRNA against survivin induced apoptosis and at-
tenuated tumor cell growth in vitro and in vivo. Molecular
Therapy. 2004;10(1):162–171.
[21] Sumimoto H, Yamagata S, Shimizu A, et al. Gene therapy
for human small-cell lung carcinoma by inactivation of Skp-
2 with virally mediated RNA interference. Gene Therapy.
2005;12(1):95–100.
[22] Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR.
Activation of the interferon system by short-interfering RNAs.
Nature Cell Biology. 2003;5(9):834–839.
[23] Sioud M. Induction of inﬂammatory cytokines and inter-
feron responses by double-stranded and single-stranded siR-
NAs is sequence-dependent and requires endosomal localiza-
tion. Journal of Molecular Biology. 2005;348(5):1079–1090.
[24] Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-
speciﬁc potent induction of IFN-alpha by short interfering
RNA in plasmacytoid dendritic cells through TLR7. Nature
Medicine. 2005;11(3):263–270.
[25] Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance
siRNA-mediated interferon response in mice. Biochemical and
Biophysical Research Communications. 2005;330(3):755–759.
[26] Manoharan M. RNA interference and chemically modiﬁed
small interfering RNAs. Current Opinion in Chemical Biology.
2004;8(6):570–579.
[27] Verma S, Jager S, Thum O, Famulok M. Functional tuning
of nucleic acids by chemical modiﬁcations: tailored oligonu-
cleotides as drugs, devices, and diagnostics. The Chemical
Record. 2003;3(1):51–60.
[28] Kurreck J. Antisense technologies. Improvement through
novel chemical modiﬁcations. European Journal of Biochem-
istry. 2003;270(8):1628–1644.
[29] ChiuYL,RanaTM.siRNAfunctioninRNAi:achemicalmod-
iﬁcation analysis. RNA. 2003;9(9):1034–1048.
[30] Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexan-
der KA. RNA interference using boranophosphate siR-
NAs: structure-activity relationships. Nucleic Acids Research.
2004;32(20):5991–6000.
[31] Braasch DA, Jensen S, Liu Y, et al. RNA interference in
mammalian cells by chemically-modiﬁed RNA. Biochemistry.
2003;42(26):7967–7975.
[32] Czauderna F, Fechtner M, Dames S, et al. Structural variations
and stabilising modiﬁcations of synthetic siRNAs in mam-
malian cells. Nucleic Acids Research. 2003;31(11):2705–2716.
[33] Hoshika S, Minakawa N, Kamiya H, Harashima H, Matsuda
A. RNA interference induced by siRNAs modiﬁed with 4 -
thioribonucleosides in cultured mammalian cells. FEBS Let-
ters. 2005;579(14):3115–3118.
[34] Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence,
chemical, and structural variation of small interfering RNAs
and short hairpin RNAs and the eﬀect on mammalian
gene silencing. Antisense & Nucleic Acid Drug Development.
2003;13(2):83–105.8 Journal of Biomedicine and Biotechnology
[35] Prakash TP, Allerson CR, Dande P, et al. Positional eﬀect
of chemical modiﬁcations on short interference RNA ac-
tivity in mammalian cells. Journal of Medicinal Chemistry.
2005;48(13):4247–4253.
[36] Layzer JM, McCaﬀrey AP, Tanner AK, Huang Z, Kay MA, Sul-
lenger BA. In vivo activity of nuclease-resistant siRNAs. RNA.
2004;10(5):766–771.
[37] MorrisseyDV,BlanchardK,ShawL,etal.Activityofstabilized
short interfering RNA in a mouse model of hepatitis B virus
replication. Hepatology. 2005;41(6):1349–1356.
[38] LiaoH,WangJH.Biomembrane-permeableandribonuclease-
resistant siRNA with enhanced activity. Oligonucleotides.
2005;15(3):196–205.
[39] Muratovska A, Eccles MR. Conjugate for eﬃcient delivery of
short interfering RNA (siRNA) into mammalian cells. FEBS
Letters. 2004;558(1–3):63–68.
[40] Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing
ofanendogenousgenebysystemicadministrationofmodiﬁed
siRNAs. Nature. 2004;432(7014):173–178.
[41] Judge AD, Bola G, Lee ACH, MacLachlan I. Design of nonin-
ﬂammatory synthetic siRNA mediating potent gene silencing
in vivo. Molecular Therapy. 2006;13(3):494–505.
[42] Carstea ED, Hough S, Wiederholt K, Welch PJ. State-of-
the-art modiﬁed RNAi compounds for therapeutics. IDrugs.
2005;8(8):642–647.
[43] de Jonge J, Holtrop M, Wilschut J, Huckriede A. Reconsti-
tuted inﬂuenza virus envelopes as an eﬃcient carrier system
for cellular delivery of small-interfering RNAs. Gene Therapy.
2006;13(5):400–411.
[44] Kimchi-Sarfaty C, Brittain S, Garﬁeld S, Caplen NJ, Tang Q,
Gottesman MM. Eﬃcient delivery of RNA interference eﬀec-
tors via in vitro-packaged SV40 pseudovirions. Human Gene
Therapy. 2005;16(9):1110–1115.
[45] Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of
hepatitis B virus from the liver of transgenic mice by short
hairpin RNAs. Proceedings of the National Academy of Sciences
of the United States of America. 2005;102(3):773–778.
[46] Dittgen T, Nimmerjahn A, Komai S, et al. Lentivirus-based
genetic manipulations of cortical neurons and their optical
and electrophysiological monitoring in vivo. Proceedings of the
National Academy of Sciences of the United States of America.
2004;101(52):18206–18211.
[47] Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoﬀ
C. Inhibiting primary eﬀusion lymphoma by lentiviral vectors
encoding short hairpin RNA. Blood. 2005;105(6):2510–2518.
[48] RalphGS,RadcliﬀePA,DayDM,etal.SilencingmutantSOD1
using RNAi protects against neurodegeneration and extends
survival in an ALS model. Nature Medicine. 2005;11(4):429–
433.
[49] Raoul C, Abbas-Terki T, Bensadoun J-C, et al. Lentiviral-
mediated silencing of SOD1 through RNA interference retards
disease onset and progression in a mouse model of ALS. Na-
ture Medicine. 2005;11(4):423–428.
[50] Bot I, Guo J, Van Eck M, et al. Lentiviral shRNA silencing of
murine bone marrow cell CCR2 leads to persistent knock-
down of CCR2 function in vivo. Blood. 2005;106(4):1147–
1153.
[51] Yi Y, Hahm SH, Lee KH. Retroviral gene therapy: safety issues
and possible solutions. Current Gene Therapy. 2005;5(1):25–
35.
[52] Palmer DJ, Ng P. Helper-dependent adenoviral vectors for
gene therapy. Human Gene Therapy. 2005;16(1):1–16.
[53] WolkowiczR,NolanGP.Genetherapyprogressandprospects:
novel gene therapy approaches for AIDS. Gene Therapy.
2005;12(6):467–476.
[54] Jia W, Zhou Q. Viral vectors for cancer gene therapy: viral
dissemination and tumor targeting. Current Gene Therapy.
2005;5(1):133–142.
[55] Wurdinger T, Verheije MH, Broen K, et al. Soluble receptor-
mediated targeting of mouse hepatitis coronavirus to the hu-
man epidermal growth factor receptor. Journal of Virology.
2005;79(24):15314–15322.
[56] Xiong Z, Cheng Z, Zhang X, et al. Imaging chemically mod-
iﬁed adenovirus for targeting tumors expressing integrin
{alpha}v{beta}3 in living mice with mutant herpes simplex
virus type 1 thymidine Kinase PET reporter gene. Journal of
Nuclear Medicine. 2006;47(1):130–139.
[57] Monahan PE, Jooss K, Sands MS. Safety of adeno-associated
virus gene therapy vectors: a current evaluation. Expert Opin-
ion on Drug Safety. 2002;1(1):79–91.
[ 5 8 ]K a p p e sJ C ,W uX .S a f e t yc o n s i d e r a t i o n si nv e c t o rd e v e l o p -
ment. Somatic Cell and Molecular Genetics. 2001;26(1–6):147–
158.
[ 5 9 ]G u oS ,T s c h a m m e rN ,M o h a m m e dS ,G u oP .S p e c i ﬁ cd e -
livery of therapeutic RNAs to cancer cells via the dimeriza-
tion mechanism of phi29 motor pRNA. Human Gene Therapy.
2005;16(9):1097–1109.
[60] Sørensen DR, Leirdal M, Sioud M. Gene silencing by systemic
deliveryofsyntheticsiRNAsinadultmice.JournalofMolecular
Biology. 2003;327(4):761–766.
[61] Luo MC, Zhang DQ, Ma SW, et al. An eﬃcient intrathecal de-
livery of small interfering RNA to the spinal cord and periph-
eral neurons. Molecular Pain. 2005;1:29.
[62] Pal A, Ahmad A, Khan S, et al. Systemic delivery of Raf-
siRNA using cationic cardiolipin liposomes silences Raf-1
expression and inhibits tumor growth in xenograft model
of human prostate cancer. International Journal of Oncology.
2005;26(4):1087–1091.
[63] Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-
based vectors for gene therapy: impact of microarray technol-
ogy. Current Drug Delivery. 2005;2(4):429–441.
[64] Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A.
RNAi-mediated gene-targeting through systemic application
of polyethylenimine (PEI)-complexed siRNA in vivo. Gene
Therapy. 2005;12(5):461–466.
[65] Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu
T. A small interfering RNA targeting vascular endothe-
lial growth factor as cancer therapeutics. Cancer Research.
2004;64(10):3365–3370.
[66] Takeshita F, Minakuchi Y, Nagahara S, et al. Eﬃcient delivery
of small interfering RNA to bone-metastatic tumors by using
atelocollagen in vivo. Proceedings of the National Academy of
Sciences of the United States of America. 2005;102(34):12177–
12182.
[67] Song E, Zhu P, Lee S-K, et al. Antibody mediated in vivo deliv-
eryofsmallinterferingRNAsviacell-surfacereceptors.Nature
Biotechnology. 2005;23(6):709–717.
[68] Pirollo KF, Zon G, Rait A, et al. Tumor-targeting nanoim-
munoliposome complex for short interfering RNA delivery.
Human Gene Therapy. 2006;17(1):117–124.
[69] Schiﬀelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by
tumor selective delivery with ligand-targeted sterically stabi-
lized nanoparticle. Nucleic Acids Research. 2004;32(19):e149.Sabrina Oliveira et al 9
[70] Kim B, Tang Q, Biswas PS, et al. Inhibition of ocular angio-
genesis by siRNA targeting vascular endothelial growth factor
pathway genes: therapeutic strategy for herpetic stromal ker-
atitis. American Journal of Pathology. 2004;165(6):2177–2185.
[71] Elbashir SM, Harborth J, Lendeckel W, Yalcin A, We-
ber K, Tuschl T. Duplexes of 21-nucleotide RNAs medi-
ate RNA interference in cultured mammalian cells. Nature.
2001;411(6836):494–498.